ArticleJMIR public health and surveillance2024
All-Cause and Cause-Specific Burden of Asthma in a Transitioning City in China: Population Study.
Article in JMIR public health and surveillance, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Thyroid disease-attributed mortality burden and temporal trends among U.S. adults aged ≥65 years, 1999-2023: a nationwide analysis based on the CDC WONDER database.Frontiers in public health · 2026Article
- Real-world analysis and future trends of parkinson's disease burden and all-cause mortality in Shanghai Pudong: a population-based study of 3.17 million people.BMC public health · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Understanding the impact of asthma on public health is crucial for evidence-based prevention and treatment strategies. Objective: This study aimed to identify the causes of asthma-related mortality in Pudong, Shanghai, China, offering insights for managing similar regions or countries in transition. Methods: Mortality statistics were obtained from the Vital Statistics System of Pudong for 2005-2021. Temporal patterns for the burden of asthma were examined. The crude mortality rate (CMR), age-standardized mortality rate by Segi's world standard population (ASMRW), and years of life lost (YLL) for both all-cause and asthma-specific deaths were computed. Mortality rates associating with aging and other variables were categorized using the decomposition technique. The autoregressive integrated moving average model was used to forecast the asthma-related death mortality rate by 2035. Results: A total of 1568 asthma-related deaths occurred during the follow-up period, with the CMR and ASMRW being 3.25/105 and 1.22/105 person-years, respectively. The primary underlying causes of death were chronic lower respiratory diseases, coronary heart diseases, and cerebrovascular disease. The YLL due to total asthma-related deaths added up to 14,837.76 years, with a YLL rate of 30.73/105 person-years. Male individuals had more YLL (8941.81 vs 5895.95 y) and a higher YLL rate (37.12/105 vs 24.38/105 person-years) than female individuals. From 2005 to 2021, the ASMRW declined by 3.48%, and both the CMR and YLL rate decreased in the 0-29, 70-79, and ≥80 years age groups (all P<.01). However, asthma-related deaths increased from 329 people between 2005 and 2008 to 472 people between 2017 and 2021. The proportion of the population aged 80 years and older gradually increased by 1.43% (95% CI 0.20%-2.68%; P=.03), and the mortality rates of asthma deaths attributable to population aging rose by 21.97% (95% CI, 11.58%-33.32%; P<.001) annually. Conclusions: Asthma remains a significant public health challenge in transitioning countries, requiring increased attention and resource allocation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.